Sandoz Group AG (SDZNY)
| Market Cap | 22.65B |
| Revenue (ttm) | 10.38B |
| Net Income (ttm) | n/a |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 15.65 |
| Dividend | 0.57 (1.09%) |
| Ex-Dividend Date | Apr 22, 2025 |
| Volume | 354 |
| Average Volume | 32,504 |
| Open | 52.05 |
| Previous Close | 53.42 |
| Day's Range | 52.01 - 52.66 |
| 52-Week Range | 35.61 - 54.49 |
| Beta | n/a |
| RSI | 62.33 |
| Earnings Date | Aug 7, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence ...
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...
Sandoz inks agreement with Shanghai Henlius for Bristol Yervoy biosimilar
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News
Switzerland's Sandoz files antitrust lawsuit against Amgen in US
Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...
Novartis After Sandoz: The Business Without Generics
Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions
La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...
Sandoz: Upgrading To A Buy On 2028 Expectations
Sandoz signs landmark supply and manufacturing agreement
BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...
Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE
BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.